Table 7. The effect of quarterly albendazole during childhood on incidence of malaria, diarrhoea, pneumonia, and eczema (15 months to 5 years).
Albendazole Placebo | Albendazole | ||
Malaria | Events (pyrs at risk ×100) | 1006 (31.67) | 845 (31.11) |
Rate per 100 pyrs | 31.77 | 27.16 | |
Hazard ratio (95% CI) | 0.85 (0.73–0.98) | ||
P value | 0.03 | ||
Diarrhoea | Events (pyrs at risk ×100) | 1173 (31.59) | 1147 (30.97) |
Rate per 100 pyrs | 37.13 | 37.04 | |
Hazard ratio (95% CI) | 0.99 (0.88–1.11) | ||
P value | 0.84 | ||
Pneumonia | Events (pyrs at risk ×100) | 211 (31.97) | 206 (31.35) |
Rate per 100 pyrs | 6.60 | 6.57 | |
Hazard ratio (95% CI) | 0.99 (0.76–1.28) | ||
P value | 0.92 | ||
Eczema | Events (pyrs at risk ×100) | 77 (32.03) | 107 (31.39) |
Rate per 100 pyrs | 2.40 | 3.41 | |
Hazard ratio (95% CI) | 1.25 (0.78–2.01)* | ||
P value | 0.36 |
Hazard Ratio adjusted for eczema prior to randomisation and maternal hookworm at enrolment.